Meeting
2019 ASCO Annual Meeting
A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.
Authors
Xing Zhang
Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-Sen University Cancer Center, Guangzhou, China
Xing Zhang , Xizhi Wen , Chen Yang , Shan Zeng , Lichuang Men , Hengbang Wang , Yuxiang Ma , Yang Zhang , Ruiqing Peng , Desheng Weng , Li Zhang , Jiao Ji , Wenqin Liu , ZHIYAN LIANG , Yingjie Huang , Dajun Yang , Yifan Zhai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
CTR20170975
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3124)
DOI
10.1200/JCO.2019.37.15_suppl.3124
Abstract #
3124
Poster Bd #
116
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.
First Author: Xing Zhang
Poster
2019 ASCO Annual Meeting
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
First Author: Drew W. Rasco
Poster
2013 ASCO Annual Meeting
A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
First Author: Geoffrey Shapiro
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer